Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov footer now identifies the site revision as v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T12:23:04.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T13:33:59.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    Access to the ClinicalTrials.gov study record for NCT03950674 now returns a 403 Forbidden page instead of the study details. The screen shows a 403 message and a Home button, signaling the record is temporarily inaccessible due to permissions.
    Difference
    22%
    Check dated 2026-09-20T04:32:31.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The page content remains unchanged; there are no new edits or additions to interpret in context.
    Difference
    0.0%
    Check dated 2026-09-13T01:56:35.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The page's revision tag was updated to v3.6.6, signaling a minor maintenance update to the record. No substantive information about the study is changed.
    Difference
    0.0%
    Check dated 2026-08-29T23:41:15.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    A new revision tag 'Revision: v3.6.5' has been added, replacing 'Revision: v3.6.4'. This indicates an updated revision history for the page.
    Difference
    0.0%
    Check dated 2026-08-08T19:52:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.